Dolasetron

Printed from https://www.cancerquest.org/patients/drug-reference/dolasetron on 04/20/2024



Brand name: Anzemet® IUPAC: (3R)-10-oxo-8-azatricyclo[5.3.1.03,8]undec-5-yl 1H-indole-3-carboxylate FDA approval: Yes <u>Manufacturer Link</u> Usage:


Dolasetron mesylate (Anzemet®) is used to the prevent nausea and vomiting associated withcytotoxic effects of chemotherapy. Dolasetron is administered in pill form. <u>1</u> In December 2010, the U.S. FDA blocked the use of the injected (intravenous) form of the drug for the prevention of nausea due to chemotherapy. <u>2</u>

- 1Anzemet.. Prescribing Information. Aventis Pharmaceuticals. September, 2016. [http://www.anzemet.com]
- <u>2</u>https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-use-anzemet-dolasetron-mesylate

Mechanism:

Dolasteron works by blocking the reception of serotonin at 5-HT3 receptors. When these receptors are bound by serotonin, they induce nausea and the vomiting reflex.

The structure below shows the 3D conformer Dolasetron.



Side effects:

The most common side effects associated with the use of Anzemet® duringchemotherapy regimens are headache, fatigue and diarrhea. The intravenous version of the drug was associated with abnormal heart rhythms.